Create Free Account

By creating account you will get access to hot stocks & personalised emails

Genetic Signatures Ltd

Healthcare AU GSS

0.705AUD
0.005(0.71%)

Last update at 2024-05-02T02:45:00Z

Day Range

0.680.72
LowHigh

52 Week Range

0.380.75
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -14.05200M 3.06M 1.76M -2.08600M -3.49199M
Minority interest - - - - -
Net income -14.05200M 3.06M 1.76M -2.08600M -3.49251M
Selling general administrative 15.04M 11.47M 10.02M 6.67M 5.51M
Selling and marketing expenses 1.28M 1.52M 1.32M 0.57M -
Gross profit 13.36M 23.43M 18.48M 6.96M 3.18M
Reconciled depreciation 1.53M 1.62M 1.43M 0.88M 0.47M
Ebit -14.05100M 3.08M 1.79M -2.05300M -3.49147M
Ebitda -12.52500M 4.70M 3.22M -1.17000M -3.02072M
Depreciation and amortization 1.53M 1.62M 1.43M 0.88M 0.47M
Non operating income net other - - - - -
Operating income -14.62200M 3.03M 1.53M -2.27600M -3.49147M
Other operating expenses 12.29M 5.35M 4.30M 5.12M 10.62M
Interest expense 0.00100M 0.02M 0.04M 0.03M 0.00052M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.12M 0.13M 0.21M 0.17M 0.00052M
Net interest income 0.54M 0.11M 0.17M -0.03300M 0.17M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.15M 0.10M 0.27M 2.67M 0.00052M
Total revenue 21.36M 35.42M 28.28M 11.26M 4.87M
Total operating expenses 28.11M 20.57M 17.12M 11.92M 8.94M
Cost of revenue 8.00M 11.99M 9.80M 4.30M 1.69M
Total other income expense net 0.15M 0.09M 0.23M 2.64M -0.00052M
Discontinued operations - - - - -
Net income from continuing ops -14.05200M 3.06M 1.76M -2.08600M -3.49199M
Net income applicable to common shares -14.05200M 3.06M 1.76M -2.08600M -3.49200M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 49.08M 59.65M 54.05M 49.72M 12.13M
Intangible assets 5.49M 1.65M 0.37M 0.10M -
Earning assets - - - - -
Other current assets 6.88M 6.88M - 2.55M 2.15M
Total liab 6.16M 4.85M 4.71M 3.79M 1.56M
Total stockholder equity 42.91M 54.80M 49.34M 45.93M 10.57M
Deferred long term liab - - - - -
Other current liab 2.30M 1.39M 1.87M 1.56M 0.98M
Common stock 84.44M 84.43M 84.16M 84.01M 47.03M
Capital stock 84.44M 84.43M 84.16M 84.01M 47.03M
Retained earnings -49.14700M -35.09500M -38.15800M -39.91400M -37.82777M
Other liab 0.10M 0.05M 0.02M 0.02M 0.02M
Good will - - - - -
Other assets - - - - -
Cash 16.35M 36.90M 30.12M 31.18M 6.31M
Cash and equivalents - - - - 6.31M
Total current liabilities 6.07M 4.80M 4.62M 3.34M 1.54M
Current deferred revenue - -0.03300M -0.33400M -0.31300M -0.31300M
Net debt -16.34900M -36.86300M -29.72200M -30.43500M -5.57055M
Short term debt 0.00000M 0.03M 0.33M 0.31M 0.31M
Short long term debt - - - - -
Short long term debt total - 0.03M 0.40M 0.74M 0.74M
Other stockholder equity -35.29100M -49.33300M -46.00600M -44.09900M 1.37M
Property plant equipment 7.22M 6.78M 6.05M 3.51M 1.46M
Total current assets 36.37M 51.23M 47.63M 46.20M 10.67M
Long term investments - - - - -
Net tangible assets 37.42M 53.16M 48.97M 45.93M 10.57M
Short term investments 10.00M 25.00M 25.00M 15.00M -
Net receivables 4.39M 4.13M 5.37M 5.22M 0.86M
Long term debt - - - - -
Inventory 8.75M 10.20M 12.13M 7.25M 1.35M
Accounts payable 3.77M 3.42M 2.75M 1.78M 0.57M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 7.62M 5.47M 3.33M 1.83M 1.37M
Additional paid in capital - - - - -
Common stock total equity - - - 84.01M 47.03M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -12.71300M -8.42200M -6.41900M -0.10100M 1.46M
Deferred long term asset charges - - - - -
Non current assets total 12.71M 8.42M 6.42M 3.51M 1.46M
Capital lease obligations - 0.03M 0.40M 0.74M -
Long term debt total 0.00000M 0.00100M 0.07M 0.43M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -8.09400M -2.98900M -4.97900M -2.35000M -0.61069M
Change to liabilities 0.51M 0.31M 0.98M 1.32M 0.28M
Total cashflows from investing activities -8.09400M -2.98900M -4.97900M -2.35000M -0.61000M
Net borrowings -0.03300M -0.36500M -0.34100M -0.29900M -0.29900M
Total cash from financing activities -0.02300M -0.10100M -0.19000M 36.69M 0.25M
Change to operating activities -4.21400M 0.20M 2.83M 0.50M 0.49M
Net income -14.05200M 3.06M 1.76M -2.08600M -3.49199M
Change in cash -20.54800M 6.78M -1.05500M 24.86M -2.64322M
Begin period cash flow 36.90M 30.12M 31.18M 6.31M 8.95M
End period cash flow 16.35M 36.90M 30.12M 31.18M 6.31M
Total cash from operating activities -12.45100M 9.81M 4.20M -9.49400M -2.26898M
Issuance of capital stock 0.01M 0.27M 0.16M 38.88M 0.26M
Depreciation 1.53M 1.62M 1.38M 0.88M 0.47M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory 1.03M 1.93M -5.15200M -5.89900M -0.17300M
Change to account receivables 0.50M 1.24M -0.29300M -4.36000M -0.10000M
Sale purchase of stock -0.00100M -0.00900M -0.01200M -1.89200M -0.00565M
Other cashflows from financing activities -0.03300M -0.36500M -0.34100M -0.29900M -0.61069M
Change to netincome 2.26M 1.44M 2.64M 0.15M 0.26M
Capital expenditures 8.09M 2.99M 4.98M 2.35M 0.61M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.52M 3.17M -5.44500M -10.25900M 0.17M
Stock based compensation 1.97M 1.92M 1.48M 0.57M -
Other non cash items 0.07M 5.13M 1.06M -8.29100M 3.02M
Free cash flow -20.54500M 6.82M -0.78400M -11.84400M -2.87967M

Fundamentals

  • Previous Close 0.70
  • Market Cap130.54M
  • Volume90479
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-16.83100M
  • Revenue TTM15.99M
  • Revenue Per Share TTM0.11
  • Gross Profit TTM 9.53M
  • Diluted EPS TTM-0.12

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GSS
Genetic Signatures Ltd		 0.005 0.71% 0.70 - 54.95 8.05 3.18 7.59 -6.2552
SHL
Sonic Healthcare Ltd		 -0.41 1.56% 25.94 24.24 17.92 1.55 1.69 1.96 10.59
HLS
Healius Ltd		 -0.05 4.35% 1.10 - 21.10 0.52 0.84 1.43 -3.5527
MVF
Monash IVF Group Ltd		 0.005 0.34% 1.46 24.42 - 2.40 2.05 2.89 13.15
IDX
Integral Diagnostics Ltd		 -0.03 1.22% 2.43 - 19.12 1.22 1.85 1.97 71.46

Reports Covered

Stock Research & News

View All

Profile

Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. In addition, it offers detection kits for gastrointestinal infections, respiratory, sexual health, anti-microbial resistance, meningitis, and tropical disease. Genetic Signatures Limited was incorporated in 2001 and is headquartered in Newtown, Australia.

Genetic Signatures Ltd

Heart Research Institute, Newtown, NSW, Australia, 2042

Key Executives

Name Title Year Born
Dr. John R. Melki BSc, Ph.D. MD, CEO & Exec. Director NA
Mr. Peter L. Manley CPA CFO & Company Sec. NA
Mr. Michael Anton Aicher BSc, M.B.A., MBA Exec. Director of US Operations & Exec. Director 1960
Mr. Christopher M. Abbott Founder & Chairman Emeritus NA
Dr. Douglas S. Millar BSc, Ph.D. Chief Scientific Officer NA
Ms. Neralie Coulston B.Sc. Global Head of Regulatory Affairs NA
Mr. Jackson Jones B.Sc. Chief Commercial Officer NA
Dr. John R. Melki BSc, Ph.D. MD, CEO & Executive Director NA
Mr. Michael Anton Aicher BSc, M.B.A., MBA Executive Director of US Operations & Executive Director 1960
Mr. Karl David Pechmann CFO, COO & Company Secretary NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.